Speakers
Alejandro Rangel
Associate Professor of Medicine
Universidad Panamericana
Day 2 afternoon
12:00 pm | Panel Discussion: Integrating Biomarkers Throughout the Trajectory of CNS Drug Discovery & Development to Guide Clinical Decisions
Andrea Crotti
Principal Scientist - Early Discovery
Takeda
Ashley Barnes
Chief Scientific Officer
Axol Bio
Track A - Day 2
11:00 am | Differentiated iPSC Co-Culture Model Development for Neurodegenerative Diseases
Beth Hoffman
Founder, President & Chief Executive Officer
Origami Therapeutics
Day 2 afternoon
4:00 pm | Exploring CNS Application of Protein Degraders to Determine Whether They Can be Utilized in a Selective Manner to Minimize Side Effects & Maximize Therapeutic Outcome
Carlos Pedraza
Director – Central Nervous System & Biology
Alkermes
Chan Tan
Principal Scientist
BridgeBio Pharma
Track B - Day 2
10:45 am | Upgrading Your Therapeutic Approach Against Alzheimer’s & Parkinson’s
Chris Winrow
Vice President & Head of Translational Medicine
Cyclerion
Day 2 afternoon
12:00 pm | Panel Discussion: Integrating Biomarkers Throughout the Trajectory of CNS Drug Discovery & Development to Guide Clinical Decisions
Track B - Day 1 PM
2:30 pm | From Concept to Clinic: Targeting the Nitric Oxide-Soluble Guanylate Cyclase-cGMP Pathway for Neurodegenerative Diseases
Cory Nicholas
Chief Executive Officer
NeuronaTx
Day 2 afternoon
5:00 pm | Uncovering Targeted Neural Cell Therapies for Chronic Disorders of the Nervous System
Craig Shering
Global Product Leader
AstraZeneca
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
9:00 am | Exploring Big Pharma’s Direction in Neurodegenerative Disease
Daniel Alkon
President –Research
Synaptogenix
Track B - Day 1 PM
2:00 pm | Uncovering Bryostatin Targets Restoration of Synaptic Wiring Lost in Alzheimer’s Degeneration
David Bearss
President and CEO
Halia Therapeutics
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
9:00 am | Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer’s
Dimitry Ofengeim
Head of Precision Neurology & Neuroinflammation
Sanofi
Pre-Conference Discussion Day
Monday, March 28, 2022
8:02 am | Defining Approaches for Precision Neurology
Eric Nelson
Senior Business Development Consultant
US HealthVest
Track A - Day 1 PM
1:14 pm | Streamlining Target Discovery
Track B - Day 1 AM
11:03 am | Analyzing the Latest Biomarkers Research to Determine Which One is the Most Useful for Neurodegenerative Disease Drug Development
George Tetz
Chief Executive Officer
CLS Therapeutics & The Human Microbiology Institute
Track A - Day 2
11:30 am | Uncovering Microbiome-Derived Therapeutic Targets to Treat Alzheimer’s Disease
Gergely Toth
Chief Executive Officer & Chief Scientific Officer
Cantabio
Graham Dempsey
Chief Scientific, Officer
Q-State Bio
Pre-Conference Discussion Day
Monday, March 28, 2022
1:03 pm | Investigating Therapeutic Discovery Platforms for Oligonucleotides Targeting Neurodegenerative Diseases
Habib Baghirov
Senior Scientific, Business Analyst
Roche
Pre-Conference Discussion Day
Monday, March 28, 2022
8:03 am | Utilizing Innovative Delivery Technology to Move Across the Blood Brain Barrier & Optimize Precision Targeting of Neurons
James Koprich
Chief Technology Officer
Atuka
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
9:30 am | Update on Animal Models of Alpha-Synucleinopathy for Use in Therapeutic Drug Development
Jamil Beg
Life Science, Venture Capitalist, & Entrepreneur
5am Ventures
Day 2 afternoon
3:00 pm | Panel Discussion: The New Landscape in NDD investing: How the 2021 Events Have Changed Outlooks
Jay Barth
Executive Vice President & Chief, Medical Officer
Lexeo Therapeutics
Track B - Day 2
11:00 am | Discovering Gene therapy for APOE4-Associated Alzheimer’s Disease
Je Min Yoo
Chief Technology Officer
BioGraphene Inc
Track A - Day 1 PM
2:30 pm | The New Target Journey: How to Progress from Target Identification & Illustrate Meaningful Effect in Pre-Clinical Models
Johanna Withers
Vice President, Clinical Development and Operations
Scipher Medicine
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
10:00 am | Precision Medicine Driven by the SPECTRA Network Biology Platform in Neurodegenerative Disorders
Johannes Krupp
Research Program Director for Neurology
Servier
Day 2 afternoon
2:30 pm | Showcasing LRRK2 Inhibitors as Treatment for Parkinson’s Disease
John Gustofson
Managing Director
AbbVie
Day 2 afternoon
3:00 pm | Panel Discussion: The New Landscape in NDD investing: How the 2021 Events Have Changed Outlooks
John Hey
Chief Scientific Officer
Alzheon
Track B - Day 1 AM
12:30 pm | Fluid & Imaging Biomarkers in ALZ-801 Development: A First-in-Class Oral Disease Modifying Agent for Alzheimer’s Disease
Jonathan Behr
Partner
Dementia Discovery Fund
Day 2 afternoon
3:00 pm | Panel Discussion: The New Landscape in NDD investing: How the 2021 Events Have Changed Outlooks
Jonathan Proto
Principal Scientist
Sanofi
Track A - Day 1 PM
2:00 pm | Learning How to Integrate Information on Cellular Communication & Pathways for a Multi-Omic Approach to Target Identification
Katherine Deng
Principal Scientist
AbbVie
Track A - Day 1 AM
11:50 am | In Vitro Transcytosis Models for BBB targeting CNS Drug Screening
Keechan Ahn
Chief Scientific Officer
Astrogen
Lisa Shafer
Chief Scientific Officer
Cerebral Therapeutics
Day 2 afternoon
2:00 pm | Analyzing Translational Approaches for Brain Targeted Drug Delivery
Magdalene Moran
President & Chief Scientific Officer
Carraway Therapeutics
Day 2 afternoon
12:00 pm | Panel Discussion: Integrating Biomarkers Throughout the Trajectory of CNS Drug Discovery & Development to Guide Clinical Decisions
Track B - Day 2
11:30 am | Enhancing Lysosomal Function as a Therapeutic Strategy for Parkinson’s Disease
Manuel Sanchez-Felix
Senior Fellow, Novel Delivery Technologies
Novartis
Track B - Day 1 PM
1:14 pm | Analyzing Key Clinical Trial Updates
Marcia Taylor
Vice President of Research
Treventis
Track A - Day 1 AM
11:20 am | Discovery of Small Molecule Dual Inhibitors of Abeta and tau Aggregation using CCM technology
Margaret Magdesian
Chief Executive Officer & Founder
Ananda Devices
Track A - Day 1 AM
12:20 pm | High Throughput Platform for Rapid Screening of Compounds on Over 3 000 Patients’ Derived Neurons in 30 Minutes
Maria Usenovic
Associate Principal Scientist
Merck
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
9:00 am | Exploring Big Pharma’s Direction in Neurodegenerative Disease
Mark Kiel, MD, PhD
Chief Scientific Officer
Genomenon
Track B - Day 1 AM
1:00 pm | An AI-Driven Locus-Specific Database (LSDB) for 35 ALS-Associated Genes
Martin Tolar
Founder, President & Chief Executive Officer
Alzheon
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
4:00 pm | ALZ-801 Phase 3 Program: Lessons & The Path Forward in Developing Targeted Therapies for Alzheimer’s Disease
Melissa Geddie
Principal Scientist – Antibody Discovery
Biogen
Michela Gallagher
Founder & Chief Executive Officer
Agene Bio
Mitesh Parekh
Account Manager
bit.bio
Track A - Day 1 AM
12:30 pm | Advancing Neurodegenerative Drug Discovery with a New Class of Consistent, Scalable Human iPSCDerived cells
Murali Gopalakrishnan
Global Head of Neuroscience Search & Evaluation
AbbVie
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
9:00 am | Exploring Big Pharma’s Direction in Neurodegenerative Disease
8:55 am | Chair’s Opening Remarks
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
8:55 am | Chair’s Opening Remarks
Neil Cashman
Chief Scientific Officer & Co-Founder
ProMIS Neurosciences
Track A - Day 1 PM
3:00 pm | Abeta oligomers in Alzheimer Disease: Target Engagement and Target Distraction
Patrick Sarmiere
Senior Director of Molecular Pharmacology
Ovid Therapeutics
Day 2 afternoon
5:30 pm | RNA interference (RNAi) Approaches for Allele Specific, Gain of Function Mutations in Rare, Monogenic Neurodevelopmental Disorders
Track A - Day 2
10:56 am | Zoning in on Neurodegenerative Disease Targets
Phllip Kong
Associate Director for Translational Medicine
Alector
Track A - Day 1 AM
11:03 am | Closing the Translational Gap: Update on Neurodegenerative Disease Models & Imaging
Piet van der Graaf
Senior Vice President, Quantitative Systems Pharmacology
Certara
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
9:30 am | How Regulatory-Ready Biosimulation is Revolutionizing Neurodegenerative Drug Development
Raj Ganesan
Senior Director -Protein Engineering & Antibody Discovery Research
Alector
Raphael Lis
Assistant Professor in Regenerative & Reproductive Medicine & Director of the Starr Foundation Stem Cell Derivation Laboratory
Weill Cornell Medicine
Rob Shaffer
Founder
Enable Therapeutics
Pre-Conference Discussion Day
Monday, March 28, 2022
1:03 pm | Targeting Glycogen in Childhood Dementia with Expansion Potential to Larger Neurodegenerative Indications
Ross Jeggo
Global Head of Neuroscience & Immuno-Inflammation Therapeutic Aria
Servier
Pre-Conference Discussion Day
Monday, March 28, 2022
1:02 pm | Exploring RNA Targeted Approaches for Rare Movement Disorders
Sam Henderson
Chief Scientific Officer
Cerecin
Day 2 afternoon
4:30 pm | Metabolic Dysfunction in Neurodegenerative Disorders: Spotlight on Parkinson’s, Huntington’s & Alzheimer’s
Sharon Rosenzweig-Lipson
Vice President of Research & Development
AgeneBio
Track B - Day 1 AM
11:20 am | How to Define Patient Selection, Selection of Optimal Intervention Points & Therapeutic Outcomes Using Biomarkers & “Prodromal AD”
Stan Chamberlain
Chief Scientific Officer
T3D Therapeutics
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
4:30 pm | Deep Diving into the Development of a PPAR Delta/Gamma Agonist T3D-959 for Alzheimer’s Disease
Steve Smith
Director of Business Development
GemPharmatech